Literature DB >> 29417360

42,573 cases of hepatectomy in China: a multicenter retrospective investigation.

Binhao Zhang1, Bixiang Zhang1, Zhiwei Zhang1, Zhiyong Huang1, Yifa Chen1, Minshan Chen2, Ping Bie3, Baogang Peng4, Liqun Wu5, Zhiming Wang6, Bo Li7, Jia Fan8, Lunxiu Qin9, Ping Chen10, Jingfeng Liu11, Zhe Tang12, Jun Niu13, Xinmin Yin14, Deyu Li15, Songqing He16, Bin Jiang17, Yilei Mao18, Weiping Zhou19, Xiaoping Chen20.   

Abstract

Hepatectomy is currently routinely performed in most hospitals in China. China owns the largest population of liver diseases and the biggest number of liver resection cases. A nationwide multicenter retrospective investigation involving 112 hospitals was performed, and focused on liver resection for patients with hepatocellular carcinoma (HCC). 42,573 cases of hepatectomy were enrolled, and 18,275 valid cases of liver resection for HCC patients were selected for statistical analysis. The epidemiology of HCC, distribution of hepatectomy, postoperative complications and prognosis were finally analyzed. In the 18,275 HCC patients, 81% had hepatitis B virus infection and 10% had hepatitis C virus infection. 38% of the HCC patients had normal Alphafetoprotein (AFP) level, and other 35% had an AFP level lower than 400 ng mL-1. In the study period, 97% of the hepatectomy for HCC were treated with open surgery, and 23.81% had vascular exclusion techniques. The operation time was (191.7±105.6) min, the blood loss was (546.0±562.8) mL, and blood transfusion was (543.0±1,035.2) mL. The median survival for HCC patients was 631 days, with 1-, 3-, and 5-year overall survival of 73.2%, 28.8% and 19.6%, respectively. Liver cirrhosis, multiple nodules, tumor thrombosis and high AFP level were risk factors that affect postoperative survival.

Entities:  

Keywords:  China; hepatectomy; hepatocellular carcinoma

Mesh:

Substances:

Year:  2018        PMID: 29417360     DOI: 10.1007/s11427-017-9259-9

Source DB:  PubMed          Journal:  Sci China Life Sci        ISSN: 1674-7305            Impact factor:   6.038


  18 in total

1.  Application of curved ablation in liver cancer with special morphology or location: Report of two cases.

Authors:  Nan Cao; Huai-Jie Cai; Xi-Xi Sun; De-Lin Liu; Bin Huang
Journal:  World J Clin Cases       Date:  2020-05-06       Impact factor: 1.337

2.  Postoperative Adjuvant Transarterial Chemoembolization Improves Short-Term Prognosis of Hepatocellular Carcinoma with Bile Duct Tumor Thrombus: A Propensity-Score Matching Study.

Authors:  Qizhen Huang; Kongying Lin; Lei Wang; Jianxing Zeng; Hongzhi Liu; Zongren Ding; Yongyi Zeng; Jingfeng Liu
Journal:  Cancer Manag Res       Date:  2020-09-28       Impact factor: 3.989

Review 3.  Combination therapy for advanced hepatocellular carcinoma: do we see the light at the end of the tunnel?

Authors:  Ti Zhang; Philippe Merle; Huaqi Wang; Haitao Zhao; Masatoshi Kudo
Journal:  Hepatobiliary Surg Nutr       Date:  2021-04       Impact factor: 8.265

Review 4.  Rationality and necessity of vascular stapler application during liver resection (Review).

Authors:  Er-Lei Zhang; Zhi-Yong Huang; Xiao-Ping Chen
Journal:  Exp Ther Med       Date:  2021-03-17       Impact factor: 2.447

5.  Liver Cancer Survival: A Real World Observation of 45 Years with 32,556 Cases.

Authors:  Jian-Guo Chen; Jian Zhu; Yong-Hui Zhang; Yong-Sheng Chen; Lu-Lu Ding; Hai-Zhen Chen; Ai-Guo Shen; Gao-Ren Wang
Journal:  J Hepatocell Carcinoma       Date:  2021-08-31

6.  Sub-Classification of Cirrhosis Affects Surgical Outcomes for Early Hepatocellular Carcinoma Independent of Portal Hypertension.

Authors:  Er-Lei Zhang; Jiang Li; Jian Li; Wen-Qiang Wang; Jin Gu; Zhi-Yong Huang
Journal:  Front Oncol       Date:  2021-05-20       Impact factor: 6.244

Review 7.  Improving the Efficacy of Liver Cancer Immunotherapy: The Power of Combined Preclinical and Clinical Studies.

Authors:  Gen-Sheng Feng; Kaisa L Hanley; Yan Liang; Xiaoxue Lin
Journal:  Hepatology       Date:  2020-11-08       Impact factor: 17.425

8.  Hepatectomy promotes recurrence of liver cancer by enhancing IL-11-STAT3 signaling.

Authors:  Dongyao Wang; Xiaohu Zheng; Binqing Fu; Zhigang Nian; Yeben Qian; Rui Sun; Zhigang Tian; Haiming Wei
Journal:  EBioMedicine       Date:  2019-07-30       Impact factor: 8.143

Review 9.  Radiofrequency ablation versus laparoscopic hepatectomy for treatment of hepatocellular carcinoma: a systematic review and meta-analysis.

Authors:  Shan Jin; Shisheng Tan; Wen Peng; Ying Jiang; Chunshan Luo
Journal:  World J Surg Oncol       Date:  2020-08-12       Impact factor: 2.754

10.  Long non-coding RNA PVT1 regulates the migration of hepatocellular carcinoma HepG2 cells via miR-3619-5p/MKL1 axis.

Authors:  Hua Liu; Yan Yin; Ting Liu; Yanying Gao; Qing Ye; Junqing Yan; Fushuang Ha
Journal:  Bosn J Basic Med Sci       Date:  2021-04-01       Impact factor: 3.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.